in past times several years, the UK has witnessed a revolution in health-related excess weight‑loss treatment options — through the introduction of semaglutide (Wegovy®) on the growing recognition of tirzepatide (Mounjaro®). Now, Yet another identify is drawing awareness in both equally clinical